SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Millennium Pharmaceuticals, Inc. (MLNM)
An SI Board Since February 1997
Posts SubjectMarks Bans Symbol
3044 135 0 MLNM
Emcee:  icanpickem Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2869Multicenter Clinical Trial of Bortezomib in Relapsed/Refractory Waldenstrom'Icebrg-6/5/2007
2868<i>Unclear to me what is meant by (-)-gossypol. Does the double negative mIcebrg-6/5/2007
2867ML: Seeking new angles for Velcade Wrapping up ASCO with subcu Velcade and dotom pope-6/5/2007
2866[Velcade and gossypol versus melanoma] >>Cell Death Differ. 2007 Jun 1; [tuck-6/5/2007
2865[Velcade and TRAIL . . . versus brain cancer] >>Clin Cancer Res. 2tuck-6/5/2007
2864New Data on Market-Leading VELCADE(R) (Bortezomib) for Injection Further StrengtIcebrg-6/4/2007
2863Study Shows VELCADE(R) Plus DOXIL(R) Improves Survival in Previously Treated PatIcebrg-6/4/2007
2862Kosan (KOSN) reported today on a Phase 1 Clinical Trial of Tanespimycin (KOS-953Icebrg-6/4/2007
2861Millennium Introduces New Oncology Molecule with Activity in Broad Range of CancIcebrg-6/4/2007
2860From FT - Drugmaker to pay if cancer treatment fails Message 23595194sim1-6/3/2007
2859VELCADE(R) (Bortezomib) for Injection Based Therapy Substantially Improves EventIcebrg-6/3/2007
2858VELCADE(R) (Bortezomib) for Injection Based Therapies Produced HighComplete RespLJM-6/3/2007
2857Combination Chemotherapy with Bortezomib, Cyclophosphamide and Dexamethasone mayIcebrg-6/1/2007
2856[Velcade and TRAIL . . . lung cancer] >>Cancer Res. 2007 May 15;67tuck-5/23/2007
2855Ortho Biotech: extended Doxil approval unlikely to significantly boost sales 22nIcebrg-5/23/2007
2854US FDA clears J&J, Millennium cancer drug combo Fri May 18, 2007 7:16pm ET16Icebrg-5/19/2007
2853Millennium Resumes Clinical Program for MLN0002 Thursday May 17, 8:01 am ET -NoIcebrg-5/17/2007
2852Myeloma bone disease and proteasome inhibition therapies. Blood. 2007 May 9 Icebrg-5/15/2007
2851Localized Treatment with a Novel FDA-Approved Proteasome Inhibitor Blocks the DeIcebrg-5/15/2007
2850Bortezomib significantly impairs the immunostimulatory capacity of human myeloidIcebrg-5/15/2007
2849Bortezomib in combination with dexamethasone for patients with relapsed Hodgkin&Icebrg-5/11/2007
2848Any good news today?tspree-5/9/2007
2847From HGSI's earnings PR today... ... The Journal of Clinical Oncology publiIan@SI-5/9/2007
2846The Velcade story Viewed as a model for how to develop cancer drugs efficiently,Icebrg-5/7/2007
2845Efficacy and safety of bortezomib in patients with plasma cell leukemia. CancerIcebrg-5/2/2007
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News